Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Mar 20  •  04:00PM ET
0.7712
Dollar change
+0.0143
Percentage change
1.89
%
Index- P/E- EPS (ttm)-1.19 Insider Own8.10% Shs Outstand12.90M Perf Week-18.83%
Market Cap10.59M Forward P/E- EPS next Y-1.04 Insider Trans0.00% Shs Float12.62M Perf Month-32.35%
Enterprise Value6.60M PEG- EPS next Q-0.29 Inst Own31.54% Short Float5.17% Perf Quarter-34.09%
Income-7.58M P/S1.12 EPS this Y-80.17% Inst Trans-1.65% Short Ratio1.28 Perf Half Y-55.16%
Sales9.44M P/B1.82 EPS next Y0.48% ROA-24.42% Short Interest0.65M Perf YTD-21.87%
Book/sh0.42 P/C1.89 EPS next 5Y- ROE-2951.24% 52W High3.13 -75.36% Perf Year-71.96%
Cash/sh0.41 P/FCF- EPS past 3/5Y63.79% 45.78% ROIC-107.09% 52W Low0.75 2.83% Perf 3Y-92.45%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-2.42% -2.71% Gross Margin99.52% Volatility9.49% 7.95% Perf 5Y-99.68%
Dividend TTM- EV/Sales0.70 EPS Y/Y TTM83.03% Oper. Margin-348.43% ATR (14)0.08 Perf 10Y-99.49%
Dividend Ex-Date- Quick Ratio0.70 Sales Y/Y TTM-13.43% Profit Margin-80.29% RSI (14)31.84 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.70 EPS Q/Q198.04% SMA20-21.76% Beta3.04 Target Price18.50
Payout- Debt/Eq0.30 Sales Q/Q-65.98% SMA50-20.71% Rel Volume0.54 Prev Close0.76
Employees34 LT Debt/Eq0.30 EarningsMar 19 AMC SMA200-47.15% Avg Volume509.83K Price0.77
IPOAug 01, 2000 Option/ShortNo / Yes EPS/Sales Surpr.382.11% -64.98% Trades Volume276,431 Change1.89%
Date Action Analyst Rating Change Price Target Change
May-19-25Resumed H.C. Wainwright Buy $17
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Mar-19-26 11:02PM
08:12PM
04:11PM
04:00PM
Mar-12-26 04:27PM
08:00AM Loading…
Jan-09-26 08:00AM
Jan-07-26 08:45AM
Dec-09-25 08:00AM
Nov-14-25 09:26AM
Nov-07-25 12:02AM
Nov-06-25 05:10PM
04:08PM
04:00PM
Oct-30-25 04:00PM
Oct-03-25 04:00PM
10:43AM Loading…
Sep-02-25 10:43AM
Aug-06-25 11:00AM
Aug-05-25 09:10AM
08:08AM
08:00AM
Aug-04-25 10:13AM
Jul-29-25 08:30AM
Jul-02-25 08:32AM
May-07-25 03:07AM
May-06-25 06:16PM
09:05AM
08:13AM
08:00AM
May-05-25 10:26AM
May-01-25 10:01AM
08:00AM Loading…
Apr-29-25 08:00AM
Apr-12-25 11:00AM
Apr-02-25 04:05PM
Apr-01-25 03:01AM
01:42AM
Mar-31-25 09:59AM
08:16AM
08:00AM
Mar-28-25 04:07PM
Dec-10-24 08:00AM
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.